Retatrutide: The Triple Agonist Explained

Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.

Reading the trial record

In the 2023 phase 2 obesity trial, 338 adults were randomized to retatrutide groups or placebo and followed for 48 weeks. The reported mean weight reduction at 48 weeks was 24.2% in the highest target-dose group and 2.1% in the placebo group. These are group averages from that study, not an individual forecast or a result from TRIUMPH-1.

Benefits must be considered alongside adverse events and withdrawals. The publication reported dose-related gastrointestinal events and increases in heart rate. The study does not establish long-term safety, outcomes after indefinite use or a consumer treatment plan. Individual photographs and social-media accounts cannot substitute for controlled evidence.

NCT04881760 is the phase 2 obesity registration. TRIUMPH-1 is NCT05929066; TRIUMPH-3 is NCT05882045. TRIUMPH-4 concerns obesity with knee osteoarthritis. A sponsor announcement, registry results and a peer-reviewed publication should be identified separately, with their dates and study populations.

How to evaluate a claim about this topic

The question "Retatrutide: The Triple Agonist Explained" needs evidence that matches the actual claim. Identify the named study, the population enrolled and the outcome measured. Check whether the result was prespecified, whether there was a relevant comparator, and whether the report includes harms as well as benefits. The studies linked below provide context; they do not establish every claim implied by this question.

Sources

• FDA: unapproved GLP-1 drugs
• Phase 2 obesity trial (NEJM, 2023)
• Phase 2 study registration (NCT04881760)